menu
    • menu

    Company profile for Affiris

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Since our founding in 2003, we have pursued our vision of using the immune system to find and fight proteins central to the development and progression of neurodegenerative diseases. Our ultimate aim is to improve the lives of patients suffering from neurodegenerative diseases, by focusing on the root cause rather than symptom management: an ethos inspired by the impact that vaccines have on health and society worldwide. We ha...
    Since our founding in 2003, we have pursued our vision of using the immune system to find and fight proteins central to the development and progression of neurodegenerative diseases. Our ultimate aim is to improve the lives of patients suffering from neurodegenerative diseases, by focusing on the root cause rather than symptom management: an ethos inspired by the impact that vaccines have on health and society worldwide. We have a broad portfolio of immunotherapy candidates which are currently in clinical trials or in preclinical development for a variety of neurodegenerative diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AffirisAustria Flag
    Country
    Country
    Austria
    Address
    Address
    Karl-Farkas-Gasse 22 1030 Vienna
    Telephone
    Telephone
    +43 (1) 798 15 75 – 300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://affiris.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
    AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

    22 Dec 2021

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/affiris-and-frontier-biotechnologies-announce-license-agreement-for-affitopeat04-an-active-immunotherapy-targeting-pcsk9-to-treat-hypercholesterolemia-in-greater-china-1642055496.pdf

    PRESS RELEASE
    22 Dec 2021
    Share Share
    AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9
    AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9

    27 May 2021

    // GLOBENEWSWIRE

    https://www.pharmacompass.com/pdf/news/affiris-positive-phase-1-results-with-immunotherapies-targeting-pcsk9-1624535329.pdf

    GLOBENEWSWIRE
    27 May 2021
    Share Share
    Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17
    Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17

    27 Apr 2021

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/positive-preclinical-in-vivo-results-with-affiris-antibody-mab-c6-17-1622609789.pdf

    PRESS RELEASE
    27 Apr 2021
    Share Share
    AFFiRiS presents positive preclinical in vivo data with antibody mAB C6-17
    AFFiRiS presents positive preclinical in vivo data with antibody mAB C6-17

    27 Apr 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=138103&sid=2

    PHARMABIZ
    27 Apr 2021
    Share Share
    AFFiRiS Announces FDA to its pre-IND Sub for Phase 2 trial with AFFITOPE PD01
    AFFiRiS Announces FDA to its pre-IND Sub for Phase 2 trial with AFFITOPE PD01

    27 Jan 2020

    // FINANCE YAHOO

    https://finance.yahoo.com/news/affiris-announces-fda-response-pre-093000849.html

    FINANCE YAHOO
    27 Jan 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search